VigiLanz Ranked No. 1 by KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance for Fourth Straight Year

Posted on February 2, 2021February 7, 2022 by Leo Bogee

The clinical surveillance company most trusted by hospitals is recognized as Best in KLAS, totaling 10 KLAS awards over 4 consecutive years

MINNEAPOLIS, Feb. 2, 2021 — VigiLanz, a clinical surveillance company, today announced that it has earned 2021 Best in KLAS designations from KLAS Research for Infection Control and Monitoring and Pharmacy Surveillance. This is the fourth year VigiLanz has been recognized by KLAS as a leader across both areas, and brings its total count of KLAS awards to 10. VigiLanz was also recognized in previous years in the Antimicrobial Stewardship category, which KLAS folded into Pharmacy Surveillance this year.

VigiLanz products earned Best in KLAS across two segments in the “2021 Best in KLAS: Software and Services” report, released on February 2:

Infection Control and Monitoring
Earning a score of 93.7, VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s EHR. Its exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“VigiLanz has been really good through the COVID-19 crisis because every time we need a new test, I just email the vendor, and they add it to the product. The vendor’s help has been a blessing.”

Physician, August 2020, klasresearch.com

Pharmacy Surveillance
Earning a score of 91.1, VigiLanz’s Dynamic PharmacoVigilance product acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for adverse drug event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“The product is extremely easy to use, and that has to be a big part of our success. Something that is hard to use or clunky wouldn’t work for our teams’ workflow. It doesn’t matter how good the quality of the material is; a clunky product wouldn’t work because we are moving at such a fast pace.

Manager, June 2020, klasresearch.com

In addition, VigiLanz’s Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, drug-bug mismatches, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and is certified by the National Healthcare Safety Network for easy, direct reporting on antibiotic use.

“I have found VigiLanz to be really helpful with their ability to fine-tune a rule and screen out a lot of noise. So we are getting exactly what we need. We can tease out geography, look at specific organisms, or look at different time frames. This is very powerful and very easy to do in the system.”

Director, January 2020, klasresearch.com

“In what’s proven to be a particularly challenging year for our hospital customers, we’re extremely proud to continue our recognition by KLAS four years in a row,” said VigiLanz Chairman and CEO David Goldsteen, MD. “We know our customers rely on us when they need it most—whether that’s triaging COVID-19 cases, monitoring the use of specific pharmaceuticals during a shortage, or saving clinicians time providing real-time alerts and reports so they can focus more on patients. It’s our job to help hospitals keep patients safe, and we’re honored to see the glowing feedback from this past year.”

Best in KLAS is a recognition given to vendors for outstanding efforts to help healthcare professionals deliver better patient care. The Best in KLAS designation is reserved for the software and services market segments that have the broadest operational and clinical impact on healthcare organizations. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

About KLAS

KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers and payers to be heard and counted. Working with thousands of healthcare professionals, KLAS gathers insights on software, services and medical equipment to deliver timely reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly represents the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit www.KLASresearch.com.

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

Media Contact
Boh Hatter
(410) 790.9570
bhatter@sage-growth.com

VigiLanz Launches New Software for Hospitals to Rapidly Deploy and Manage COVID-19 Mass Vaccination Events for Healthcare Workers

Posted on December 16, 2020January 11, 2022 by Leo Bogee

VigiLanz Vaccinate helps hospitals manage their COVID-19 risk, reduce vaccine waste, and automate data collection for CDC and state reporting

MINNEAPOLIS – Dec. 16, 2020 – VigiLanz, a clinical surveillance company, today announced the launch of a new mass vaccination support software, built on its leading enterprise software platform. VigiLanz Vaccinate provides end-to-end management of the entire vaccination process, enabling hospitals to maximize the success of mass vaccination events for healthcare workers. Especially critical now, as hospitals seek to protect staff members and patients from COVID-19 transmission, VigiLanz Vaccinate can also be used to manage annual influenza vaccination and other events. Current customers are being given priority access to the software, at no cost.

“It’s critical for hospitals to rapidly roll out the COVID-19 vaccine to staff—not only to keep frontline healthcare workers safe, but also to protect their families and the patients they work with until the vaccine is available to everyone,” said Stacy Pur, VigiLanz’s VP of Product Development. “The COVID-19 vaccine presents some unique challenges for mass vaccination events, as it expires quickly once thawed and requires two doses spaced at specific intervals. VigiLanz Vaccinate was designed to help manage this process, ensuring the maximum number of staff receive the vaccine as efficiently as possible.”

VigiLanz Vaccinate streamlines vaccine administration and management by making it easy for staff to register and provide consent, while automating workflows for program administrators. Its real-time insights into volume needs reduce vaccine waste, while analytics give visibility into vaccination and immunity rates at the individual, department, hospital, and system-level. The software issues automated reminders to healthcare staff to register and attend appointments for both vaccine doses, and report any side effects. In addition, it collates data for critical reporting back to the Centers for Disease Control (CDC), Vaccine Adverse Event Reporting System (VAERS), and the state, for immunity rates and any adverse side effects.

“The COVID-19 issue is personal—at VigiLanz, we have had employees and family members contract COVID-19 and require medical intervention,” said David Goldsteen, VigiLanz’s CEO. “We are so grateful for the amazing care healthcare teams are delivering across the country, and we wanted to do something to help. We’re proud of this demonstration of innovation and agility from our product team. When the pandemic hit, we created COVID Quick Start, a software module to help hospitals quickly implement a COVID-19 infection prevention solution. Now, with VigiLanz Vaccinate, we’ve rapidly developed and deployed an offering that our team saw a critical need for—helping frontline healthcare workers get vaccinated against COVID-19 as quickly and efficiently as possible. It was important to us to offer this tool to current customers for free to help them and their frontline healthcare teams stay safe during this extremely challenging global pandemic. It’s the right thing to do.”

VigiLanz is prioritizing current customer implementations to ensure their needs are met, with plans to accept future-customer inquiries as early as January 2021. Please direct requests to vaccinate@vigilanzcorp.com, and learn more at Vigilanzcorp.com/vaccinate.

###

About VigiLanz

Media Contact
Vanessa Ulrich
(410) 534.1161
vulrich@sage-growth.com

VigiLanz Launches COVID Quick Start, a Respiratory Viral Illness Prevention Software, Partnering with Datica for Rapid Deployment

Posted on May 20, 2020November 3, 2022 by Leo Bogee

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months

MINNEAPOLIS – May 20, 2020 – VigiLanz, a clinical surveillance company, today announced COVID Quick Start – a new solution that will enable hospitals to prepare for, prevent, and respond to the spread of COVID-19 and other respiratory viral illnesses. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Partnering with Datica for rapid deployment and supported by a team of VigiLanz’s certified infection preventionists, the software is designed to alleviate the burden on hospital IT resources and clinical staff while increasing patient safety. The solution is available for free for the first six months, with flexible financing options thereafter.

Learn more

COVID Quick Start uses VigiLanz’s clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. The platform continuously pulls patient data from a variety of sources, including EHRs, and evaluates that data against rules that issue real-time alerts to clinical staff. The rules are designed to identify potential respiratory viral illnesses, ensuring early isolation and management of patients, and can also track disease clusters to identify local outbreaks and hospital acquisition.

“Our team recognized that VigiLanz’s software and expertise could be tailored to address the unique issues presented by this pandemic and other potential respiratory viral illnesses, and that we could design a solution with a low barrier to entry,” said Stacy Pur, Vice President of Product Development at VigiLanz. “We’ve built COVID Quick Start as a solution that works both for hospitals with well-funded infection prevention programs, and those where resources may be more restricted. These organizations are facing a possible second wave of COVID-19 on top of the upcoming influenza season. Our Quick Start solution, which provides the basics of what hospitals need to monitor – such as exposures, early case identification, COVID-19 state and federal reporting requirements, and isolation – will help hospitals quickly prepare for what is coming.”

Recognizing the urgency for hospitals to have a solution like this in place, COVID Quick Start uses VigiLanz Connect, an API solution for hospital EHRs, powered by Datica, to deliver an even faster integration. This solution minimizes the burden on hospital IT resources and enables COVID Quick Start to begin improving patient safety as quickly as possible.

“Datica has deep expertise, with over 400 successful EHR integrations,” said Dave Levin, MD, Chief Medical Officer at Datica. “We’re proud to collaborate with VigiLanz as their EHR integration partner to quickly launch their COVID Quick Start product.”

COVID Quick Start provides an easy and low-risk entry to the full suite of VigiLanz’s SaaS-based clinical surveillance solutions. VigiLanz helps health systems avoid or minimize harm, optimize clinical outcomes, and support preventive care by aggregating and monitoring disparate data in real time from across the EHR and other health system databases. VigiLanz was ranked No. 1 by KLAS Research this year across three categories – Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the third year in a row it has earned Category Leader designations from KLAS.

Learn more about COVID Quick Start at vigilanzcorp.com/covid-19/.

###

About VigiLanz

About Datica

Datica is the only managed service provider (MSP) that solves healthcare’s biggest roadblocks–EHR integration and cloud compliance. Its integration solution enables data integration from any source, to any destination, in any format – without sacrificing PHI security. Datica’s cloud compliance solution offers end-to-end managed services for digital innovators to scale rapidly in the cloud, while ensuring HIPAA compliance and HITRUST certification are in place.

With over 400 live integrations and compliant cloud infrastructure for Fortune 500 companies, Datica’s deep expertise gives you the confidence and infrastructure to scale quickly and securely. For more info, visit:https://datica.com.

VigiLanz Announces Precision Dosing Powered by Tabula Rasa HealthCare’s DoseMeRx

Posted on April 2, 2020May 20, 2020 by Leo Bogee

DoseMeRx to integrate with VigiLanz clinical surveillance solutions for hospitals

MOORESTOWN, N.J., (April 02, 2020) – Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, has partnered with VigiLanz®, the leading provider in clinical surveillance, to integrate with DoseMeRx™, TRHC’s precision dosing solution. The integration of DoseMeRx within VigiLanz’s award winning software platform will provide hospital customers with instant access to personalized dosing for vancomycin and other antimicrobials, optimizing pharmacy workflow and improving patient safety.

Learn more

VigiLanz is the 2020 Category Leader for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance by KLAS Research. This is the third consecutive year, VigiLanz ranked top for Pharmacy Surveillance and second year in a row ranking top for Antimicrobial Stewardship and Infection Control and Monitoring.

“Our partnership with Tabula Rasa HealthCare and DoseMeRx enables providers to easily optimize the dosing of vancomycin and other high-risk antimicrobials,” said VigiLanz Chairman and CEO David Goldsteen, MD. “This is especially critical with the release of the new vancomycin dosing guidelines, which are indicative of a growing trend toward increased medication safety. DoseMeRx brings immense value to pharmacists. Together, we’re excited to bring precision dosing to our customers.”

The VigiLanz platform provides leading pharmacy surveillance and antimicrobial stewardship solutions for hospitals to generate real-time alerts that help clinicians make appropriate drug therapy decisions. Adding DoseMeRx will enable VigiLanz customers to easily implement the new national dosing guidelines for vancomycin – one of the most commonly used antibiotics in hospitals today.

“This partnership means convenient access for VigiLanz customers to the precision dosing capabilities of DoseMeRx to optimize the use of vancomycin in the acute care setting,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “Our goal is to expand and scale the use of DoseMeRx, along with other TRHC platforms, to more pharmacists who will use it to optimize medication safety. This partnership does just that.

According to TRHC Executive Vice President for DoseMe/Hospitals Business Unit Charles Cornish, the opportunity to integrate DoseMeRx with the VigiLanz solution is of benefit to customers looking for a closed-loop solution to clinical surveillance and dose optimization. “VigiLanz and TRHC share the common goal of building easy-to-use clinical decision software with the ability to improve workflows and support pharmacists,” said Cornish.

About Tabula Rasa HealthCare
TRHC (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. TRHC provides solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com.

About DoseMeRx

DoseMeRx is a Tabula Rasa HealthCare (NASDAQ: TRHC) solution. It is the first precision dosing software developed specifically for clinical practice. The DoseMeRx clinical decision support platform empowers healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information on DoseMeRx, visit doseme-rx.com

About VigiLanz

Founded in 2001, VigiLanz is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. To learn more about VigiLanz Precision Dosing, powered by DoseMeRx, visit info.vigilanzcorp.com/precision-dosing.

Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

VigiLanz Recognized for High Customer Retention, Innovation in KLAS 2019 Infection Control Report

Posted on March 14, 2019January 11, 2022 by Leo Bogee

MINNEAPOLIS – March 14, 2019 – VigiLanz, a clinical surveillance company, has been featured in the Infection Control 2019 Report from KLAS Research, released today. The report aggregates and analyzes interviews from thousands of healthcare professionals about the products and services their organizations use.

In the report, KLAS characterizes VigiLanz as a market leader for its high customer retention and innovative technology additions, such as active alerting, in its Dynamic Infection Control Monitor product. VigiLanz is also recognized for providing advanced automation and predictive analytics, two capabilities KLAS identified as highly desired by the market.

“Before we had [VigiLanz’s] Dynamic Infection Control Monitor, I did everything with manual data extraction,” said one anonymized user in the report. “I would have to run about 12 different reports to even get a list of patients to perform surveillance on, and I would need another six reports to get all the communicable disease reporting. [The] Dynamic Infection Control Monitor has made my job so much easier. It is a lot more efficient. I can easily get my patient list and go through it.”

Another anonymized user said, “We consider VigiLanz to be the leader in surveillance because of the flexibility of what we can do with the surveillance.”

VigiLanz’s Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with EMR systems. Its automatic exception-based alert system continuously surveils all patient records to alert decision makers in real time of potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern, and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

“We understand how critical an infection prevention product is for patient outcomes and hospitals’ bottom lines, and we’re dedicated to the ongoing innovation that ensures we continue delivering what patients and the market needs,” said David Goldsteen, MD, CEO of VigiLanz. “In general, healthcare executives say infection prevention is one of the top five uses of clinical surveillance technology,[1] and it has rapidly become a critical component of quality patient care.”

The other top uses of clinical surveillance technology, according to healthcare executives, are:

1) Identifying adverse drug events
2) Promoting antimicrobial stewardship
3) Patient safety alerting
4) Managing readmissions

In addition to being a leader in this report, KLAS recognized VigiLanz in the 2019 Best in KLAS report, earning 2019 Category Leader designations for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance.

About KLAS

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EMR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

[1] Market Report: Clinical Surveillance: The Next Step in Value-Based Care. Feb. 2019. VigiLanz.

IllumiCare and VigiLanz Partner to Help Pharmacists and Clinicians Advance Antimicrobial Stewardship

Posted on February 6, 2019January 11, 2022 by Leo Bogee

Houston Methodist Sugar Land Hospital first in country to launch new point-of-care alert solution with pharmacist-only rollout.

BIRMINGHAM, HOUSTON, & MINNEAPOLIS – February 6, 2018 – The CDC estimates that 20 to 50 percent of antibiotics prescribed in U.S. acute-care hospitals are unnecessary or inappropriate. With the need for healthcare systems and federal agencies to increase their focus on antibiotic stewardship, both providers and pharmacists play a vital role in monitoring safe and appropriate use. Today, VigiLanz, a clinical surveillance company, and IllumiCare, a leading provider of point-of-care technology, announce a partnership to increase visibility within providers’ and pharmacists’ normal workflows around antimicrobial therapy monitoring.

IllumiCare’s Smart Ribbon^® is an EMR-agnostic, non-intrusive ribbon of information that hovers over the EMR and provides patient-specific information such as the costs and risks of medications and tests, opioid exposures, and more. The Smart Ribbon displays VigiLanz’s Antimicrobial Stewardship Solution in a more visible, convenient and accessible place in the EMR when the provider or pharmacist is making care decisions. With this ability to respond to context in real-time, the Smart Ribbon only delivers notifications on issues or opportunities that busy clinicians and pharmacists can personally act on. This increases engagement with the VigiLanz insights and saves pharmacists the time and energy often spent tracking down a clinical counterpart to resolve an activation that’s halting the workflow.

“One key element to promoting antimicrobial stewardship is making sure the information is easily accessible to the right clinician or pharmacist when they need it most,” said GT LaBorde, CEO of IllumiCare. “VigiLanz provides real-time information related to safe antibiotic use that can reduce overprescribing or inappropriate prescribing and ultimately, lower costs. By making this information not only easier to see and more actionable, but also appropriately tailored to the person taking the action, antimicrobial stewardship efforts will be more successful.”

Houston Methodist Sugar Land Hospital is the first health system to deploy the VigiLanz clinical surveillance alerts within IllumiCare’s Smart Ribbon. Pharmacists can choose to engage with VigiLanz activations by viewing them, marking them as necessary and providing comments, all within their current workflow in the EMR. One of the most important activations is the visibility of drug-bug mismatches, in which the antimicrobial a patient receives is not adequate for the microbiological organism presumed to be causing the clinical infection. Additionally, the VigiLanz alerts highlight broad antimicrobial use, de-escalation opportunities, and conversion opportunities to move the patient to an antibiotic that has equal efficacy but is less expensive, such as from IV drugs to oral medications.

“Having actionable insights into antimicrobial use is critical; being able to put those insights in front of clinicians and pharmacists at the point of care is industry-leading,” said David Goldsteen, MD, CEO of VigiLanz. “We’re thrilled to be partnering with IllumiCare to deliver our trusted clinical surveillance insights through their Smart Ribbon to those who take action, ensuring safe and appropriate antimicrobial use.”

For more information, visit Illumicare at www.illumicare.com and VigiLanz at www.vigilanzcorp.com

VigiLanz Ranked No. 1 by KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance

Posted on January 31, 2019January 24, 2023 by Leo Bogee

MINNEAPOLIS – Jan. 31, 2019 – VigiLanz, a clinical surveillance company, today announced that it has earned 2019 Category Leader designations from KLAS Research for Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance.

This is the second year VigiLanz has earned the No. 1 distinction for multiple categories. The company previously achieved Category Leader status in 2018 for Infection Control and Monitoring and Pharmacy Surveillance. Antimicrobial Stewardship is a new KLAS category for 2019.

Three VigiLanz products were recognized in the “2019 Best in KLAS: Software and Services” report, released on January 31:

VigiLanz Dynamic Infection Control Monitor

Earning a score of 90.6, the Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Its automatic exception-based alert system puts all patient records under continuous surveillance to alert decision makers in real time of potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of customizable rule engines.

VigiLanz Dynamic PharmacoVigilance

Earning a score of 93.0, Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, it automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

VigiLanz Antimicrobial Stewardship

Earning a score of 94.6, the Antimicrobial Stewardship product monitors antimicrobial therapy to ensure appropriate use, including unnecessary antibiotic therapy, de-escalation opportunities, positive rapid diagnostic test results, and opportunities for antibiotic “time-outs.” The Antimicrobial Stewardship dashboard shows usage and resistance trends across the organization, is Meaningful Use 3 certified, and provides direct reporting to the Centers for Disease Control’s National Healthcare Safety Network.

“It’s an honor to be recognized by KLAS as a leader in multiple categories for the second time, validating the confidence and trust we know our customers have in our clinical surveillance products,” said VigiLanz Chairman and CEO David Goldsteen, MD. “KLAS’ global reputation for accurately and impartially measuring vendor performance is an unparalleled channel for customer feedback – something we find invaluable to our culture of continued innovation. We look forward to continuing to provide industry-leading solutions to hospitals across the country that improve the safety and quality of patient outcomes.”

The KLAS Category Leader designation is awarded to vendors that lead select market segments in which at least two products meet a minimum number of KLAS Konfidence reviews. Rankings are based on customer surveys of North American healthcare leaders, administrators, clinicians, and others who interact with the solutions.

About KLAS

About VigiLanz

Founded in 2001, VigiLanz (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care.

VigiLanz and Cincinnati Children’s Collaborate to Commercialize a Real-Time Solution to Minimize Acute Kidney Injury in Pediatrics

Posted on November 29, 2018January 11, 2022 by Leo Bogee

MINNEAPOLIS & CINCINNATI – (November 29, 2018) – VigiLanz and Cincinnati Children’s Hospital Medical Center today announced a collaboration that leverages Cincinnati Children’s ground-breaking research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for Acute Kidney Injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

“Pediatric acute kidney injury is a serious problem that traditionally could not be identified in real-time, which impacted our ability to identify the patients who most needed treatment,” stated Dr. Stuart L. Goldstein, MD, FAAP, FNKF, Director of the Center for Acute Care Nephrology and primary researcher on NINJA. “By partnering with VigiLanz, Cincinnati Children’s is applying our unprecedented research to a commercially-available solution that accurately characterizes pediatric AKI epidemiology, reducing AKI and improving patient outcomes.”

Commercially available to hospitals and health systems focused on mitigating pediatric AKI, NINJA automates a time-consuming manual screening process that includes evaluating patients for exposure to 57 nephrotoxic medications, imaging contrast dye, and recent renal testing. For medications, manual screening is limited to the last 24 hours, while the contrast dye evaluation requires reviewing records for the previous seven days to determine if it was received by the patient.

Leveraging NINJA algorithms built into VigiLanz rules, an AKI monitoring dashboard lists all patients that meet the NINJA exposure criteria as well as the criteria that put the patient in the at-risk category. These criteria include medication exposure, serum creatinine data, and patient history of AKI. When patients meet at-risk criteria, they are placed on the monitoring list in real time, where they remain until 48 hours after their risk has passed.

The platform also features metric outputs that can be customized with respect to service lines and time periods, while robust reporting tools provide the ability to trend conditions over time via automated run charts. It also enables automatic and customizable data extraction for all metric elements, including inpatient census by location or service line.

“By expanding awareness of the extensive research conducted by Cincinnati Children’s, this partnership will help drive improvements in pediatric AKI outcomes,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Those improvements can be realized quickly, too, as the NINJA dashboard is not just a concept but rather a tangible solution now available to any hospital interested in limiting AKI associated with nephrotoxic drugs.”

About VigiLanz

Founded in 2001, VigiLanz Corporation (www.vigilanzcorp.com) is a privately held, rapidly growing provider of SaaS health care intelligence and predictive analytics. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care along the entire health system continuum. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. VigiLanz is shaping the emerging era of real-time health care by delivering enterprise intelligence technology and services that improve clinical outcomes, patient care and operational effectiveness.

Connexall and VigiLanz Combine Antimicrobial Stewardship with Intelligent Routing to Improve Patient Safety

Posted on February 28, 2018January 24, 2023 by Leo Bogee

BOULDER, CO & TORONTO, ON – (February 28, 2018) – Connexall and VigiLanz, both named Category Leaders in the 2018 Best in KLAS awards, have teamed up to deliver time-sensitive information related to antimicrobial stewardship (AMS) to increase patient safety and improve outcomes at hospitals.

The VigiLanz AMS platform aggregates information from physician order entries, laboratory and pathology reports, and the EHR to provide continuous surveillance of patients. Connexall integrates with VigiLanz and the EHR to intelligently route data quickly and reliably to the assigned care team for the affected patient. This guides the care team to ensure safe and appropriate use of antibiotics.

“AMS has emerged as a central component of highly effective care quality and safety strategies, and success requires the ability to rapidly transform data into action,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “This partnership between VigiLanz and Connexall does just that, providing our customers with a robust AMS solution that leverages the power of two KLAS category leaders to drive improved patient outcomes.”

“Connexall is delighted to partner with VigiLanz to enhance antimicrobial stewardship programs for the benefit of patients.” stated David Tavares, GlobeStar/Connexall CEO. “Our intelligent routing capabilities ensure that the assigned care team is notified promptly and reliably to deliver the care the patients require.” continued Tavares.

To learn more about this progressive solution, please visit VigiLanz at Booth #2674 and Connexall at Booth #8105 at HIMSS18.

About Connexall

Connexall, ranked number one and named Category Leader in the 2015/2016, 2017, and 2018 Best in KLAS awards, is an enterprise-grade event management and control platform that delivers hospital-wide interoperability to people, systems, tasks, and devices. Its capabilities act as a backbone for clinical workflow, communicating the right information to the right person, at the right time, on the right device. Based on more than 20 years of R&D efforts, the Class II medical device software is completely vendor-neutral and device-independent. Connexall has offices in Canada, the United States, Brazil, Portugal and Hong Kong and works with well over a thousand of the world’s most renowned and progressive hospitals and health systems. For more information please visit www.connexall.com.

About VigiLanz

VigiLanz Ranked #1 in Best in KLAS Report for Infection Control and Clinical Decision Support-Surveillance Categories

Posted on January 31, 2018January 11, 2022 by Leo Bogee

MINNEAPOLIS – (January 31, 2018) – VigiLanz, a digital healthcare intelligence firm, announced today that it has earned 2018 Category Leader designations for Infection Control and Clinical Decision Support-Surveillance in the 2018 Best in KLAS: Software and Services report. These mark the second and third KLAS honors in the past year for VigiLanz, which also achieved the top overall satisfaction rating in the “Antimicrobial Stewardship 2017” performance report for its platform, customer partnerships, and dedication to customer service and support.

In the “2018 Best in KLAS: Software and Services,” report, released on January 30, VigiLanz’s Dynamic Infection Control Monitor product garnered a score of 90.3 while its Dynamic PharmacoVigilance product earned an 89.9.

The Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence. Rankings are based on customer surveys of North American hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment solutions.

Dynamic Infection Control Monitor is a seamless, real-time automated monitoring system that works with an organization’s standard EHR system. Via an automatic exception-based alert system, all patient records are under continuous surveillance to alert decision makers in real time to potential infections, drug-bug mismatches, MDROs, isolation candidates, organism clusters, conditions of concern and reportable infections. The surveillance is based on a sophisticated set of rule engines that can be customized for each hospital.

Dynamic PharmacoVigilance acts as a bridge between a hospital’s pharmacy and lab information systems, automating the comparison of patients’ drug usage with lab results, then presenting the potential for Adverse Drug Event reduction. Based on the system’s built-in rule sets or hospital-specific guidelines, the system automatically generates warnings and alerts that help clinicians make appropriate drug therapy decisions.

“VigiLanz is honored to see our solutions recognized as Category Leaders, particularly as healthcare professionals are the engine that drives KLAS’ impartial research on the software and services used by providers worldwide,” said VigiLanz Chairman and CEO Dr. David Goldsteen, MD, MBA. “Following upon VigiLanz’ recognition by KLAS in 2017 for our Antimicrobial Stewardship products, these additional designations further validate our reputation among clinicians and administrators alike as a company that offers the best, top-performing solutions in the industry.”

About KLAS

About VigiLanz